Transcatheter interventions for structural heart disease represent an emerging field in interventional
cardiology. Undoubtedly, there is an absolute necessity for antiplatelet and/or anticoagulation treatment prior,
during and post such interventions. However, currently administered regimens are mainly based in expert consensus
recommendations. In the present review we aim to summarize data regarding anti platelet and/or anticoagulation
treatment in the following transcatheter structural heart interventions: left atrial appendage closure, atrial
septal defect closure, patent foramen oval closure, paravalvular leak closure.
Keywords: ASD, LAA, PFO, transcatheter, warfarin, coumadin, antiplatelet, NOAC.
Rights & PermissionsPrintExport